You are here: Home » Companies » News
Business Standard

Boost to Biocon's biosimilar business as Bengaluru units get European nod

Facilities were inspected by the European Medicines Agency in March; Analysts foresee firm posting double-digit growth in revenue and profits despite rising competition

Gireesh Babu  |  Chennai 

Employees of Biocon Ltd work inside the company's research and development centre in Bengaluru. File photo: Reuters
Employees of Biocon Ltd work inside the company's research and development centre in Bengaluru. File photo: Reuters

has received the European drug regulatory agency's approval for its facilities in Bengaluru, enabling it to continue and enhance its production for the Continent's markets.

The company said on Friday that it has received the Certificate of GMP (Good Manufacturing Practice) compliance from (EMA) for its Biologics Drug Product (DP) and Drug Substance (DS) facilities at Park, Bengaluru. The facilities, which manufacture Biocon’s portfolio of biosimilars, were inspected by the European agency in March 2019.

"This was a surveillance inspection of our existing DP and DS facilities and a pre-approval inspection of our additional DP manufacturing line. This certification will enable us to continue addressing the growing needs of patients in the EU markets and enhance access to our high quality biosimilars,” said company spokesperson in a statement issued today.

The company is expected to deliver growth in the biologics business from product launches in developed and emerging markets, along with a pipeline of biosimilars for launch in future. Analysts earlier said that the growth from biologics business is expected to post double-digit growth both, in revenue and net profit, over the next three financial years, even though competition is expected to grow in future.

First Published: Fri, June 14 2019. 16:00 IST
RECOMMENDED FOR YOU